Announcement of capital and business alliance with Mitsui Chemicals, Inc.

NATiAS Inc. (Head office: Chuo-ku, Kobe; CEO: Masanori Kataoka) is pleased to announce that NATiAS has agreed to a third-party allotment of new shares with Mitsui Chemicals, Inc. (Head office: Minato-ku, Tokyo; President & CEO: Osamu Hashimoto) forming a business alliance.

Through this capital and business alliance, we will strengthen our Blockmer™ intermediates and oligonucleotide therapeutics CDMO businesses by leveraging Mitsui Chemicals’ strengths in enzyme technology and precision organic synthesis technology and our liquid-phase synthesis technology which will enable high quality and large volume production of oligonucleotide APIs.

In particular, as for our core oligonucleotide therapeutics CDMO business, we will expand our operational capability so that we can handle from basic and clinical research to post-approval activities through the establishment of a new GMP facility.

Contacts

NATiAS Inc.
CFO Yosuke Suzuki
TEL：+81-78-599-9495
Contact Form：https://www.natias.co.jp/index.php/en/contact-2/

Mitsui Chemicals, Inc. 
Corporate Communications Dept.
TEL：+81-3-6253-2100
Contact Form：https://form.mitsuichemicals.com/corporate/cc_pr_csr_ja